Kinomica, King's College London, and King's College Hospital NHS to Present Research at 2024 ASCO Meeting

Kinomica Ltd., a leading developer in precision oncology diagnostics, has announced a significant collaboration with King's College London and King's College Hospital NHS Foundation Trust. This partnership will present its groundbreaking research at the American Society of Clinical Oncology (ASCO) annual meeting, scheduled for May 31 to June 4, 2024, in Chicago, Illinois.

Debashis Sarker, a prominent figure in experimental oncology and a Consultant Medical Oncologist at King's College Hospital, will showcase the results of this collaborative effort. The presentation, titled "Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC)," will reveal new insights into the predictive biomarkers for immunotherapy responses in advanced liver cancer patients. This significant poster will be on display during the Developmental Therapeutics—Immunotherapy session on Saturday, June 1, 2024, from 9:00 AM to 12:00 PM CDT.

Dr. Sarker emphasized the importance of this research, noting that it is the first time a promising biomarker signature has been identified to predict responses to the immunotherapy drugs atezolizumab and bevacizumab in patients with aHCC. The study's uniqueness lies in its use of real-world Tru-Cut biopsies taken at the time of diagnosis, providing robustness to their potential clinical application.

Tim Fell, Executive Chair of Kinomica, highlighted the multidisciplinary nature of this research and the valuable clinical proteomic data employed. He expressed optimism about extending this collaborative research to identify predictive biomarkers for other approved aHCC therapies, with the ultimate goal of developing a multi-drug diagnostic tool to aid in therapy selection.

Kinomica has developed KScan®, a phosphoproteomic diagnostic platform designed to help clinicians maximize the potential of precision medicine. This platform aims to predict which approved drugs will be most effective for individual patients, thereby aiding in clinical decision-making. Kinomica's participation in the ASCO meeting represents an opportunity to forge new collaborations and expand the impact of their research.

King's College Hospital NHS Foundation Trust, one of the largest and busiest teaching hospitals in the UK, is internationally renowned for its specialties, including liver disease, neurosciences, cardiac care, haemato-oncology, fetal medicine, stroke, and major trauma. The Trust operates multiple hospitals, including King's College Hospital (Denmark Hill), the Princess Royal University Hospital (PRUH), and Orpington Hospital, among others. Serving 1.5 million patients across South London and parts of Kent, the Trust is dedicated to delivering exceptional healthcare services.

King's Health Partners, an Academic Health Science Centre, integrates research, education, and clinical practice across three NHS Foundation Trusts—Guy's and St Thomas', King's College Hospital, and South London and Maudsley—alongside King's College London. This partnership aims to translate scientific research into practical healthcare improvements, benefiting the patients and communities they serve. King's Health Partners supports nearly 40,000 students from 190 countries and employs around 45,000 staff who conduct approximately 4.8 million patient visits annually.

Kinomica's announcement and the upcoming presentation at ASCO underscore the significant advancements in precision oncology diagnostics, particularly in hepatocellular carcinoma therapy. The collaborative efforts of Kinomica, King's College London, and King's College Hospital NHS Foundation Trust exemplify the potential of combining multidisciplinary expertise and clinical data to enhance patient outcomes in cancer treatment.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!